 LAUSANNE, Switzerland--BUSINESS WIRE--ADC Therapeutics SA NYSE: ADCT, a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates ADCs for patients with hematologic malignancies and solid tumors, announced today that Joseph Camardo, MD, Chief Medical Officer, and Jennifer Herron, Chief Commercial Officer, will participate in a fireside chat at Morgan Stanleys 19th Annual Global Healthcare Conference 